» Articles » PMID: 18667857

Inhibition of Escherichia Coli O157:H7 Attachment by Interactions Between Lactic Acid Bacteria and Intestinal Epithelial Cells

Overview
Date 2008 Aug 1
PMID 18667857
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

The intestinal epithelial cell (IEC) layer of the intestinal tract makes direct contact with a number of microbiota communities, including bacteria known to have deleterious health effects. IECs possess innate protective strategies against pathogenic challenge, which primarily involve the formation of a physicochemical barrier. Intestinal tract mucins are principal components of the mucus layer on epithelial surfaces, and perform a protective function against microbial damage. However, little is currently known regarding the interactions between probiotics/pathogens and epithelial cell mucins. The principal objective of this study was to determine the effects of Lactobacillus on the upregulation of MUC2 mucin and the subsequent inhibition of E. coli O157:H7 attachment to epithelial cells. In the current study, the attachment of E. coli O157:H7 to HT-29 intestinal epithelial cells was inhibited significantly by L. acidophilus A4 and its cell extracts. It is also important to note that the expression of MUC2 mucin was increased as the result of the addition of L. acidophilus A4 cell extracts (10.0 mg/ml), which also induced a significant reduction in the degree to which E. coli O157:H7 attached to epithelial cells. In addition, the mRNA levels of IL-8, IL-1beta, and TNF-alpha in HT-29 cells were significantly induced by treatment with L. acidophilus A4 extracts. These results indicate that MUC2 mucin and cytokines are important regulatory factors in the immune systems of the gut, and that selected lactobacilli may be able to induce the upregulation of MUC2 mucin and specific cytokines, thereby inhibiting the attachment of E. coli O157:H7.

Citing Articles

Gut Goo: Physiology, Diet, and Therapy of Intestinal Mucus and Biofilms in Gastrointestinal Health and Disease.

Damianos J, Abdelnaem N, Camilleri M Clin Gastroenterol Hepatol. 2024; 23(2):205-215.

PMID: 39426645 PMC: 11761393. DOI: 10.1016/j.cgh.2024.09.007.


The role of gut microbiota augmentation in managing non-alcoholic fatty liver disease: an in-depth umbrella review of meta-analyses with grade assessment.

Maddineni G, Obulareddy S, Paladiya R, Korsapati R, Jain S, Jeanty H Ann Med Surg (Lond). 2024; 86(8):4714-4731.

PMID: 39118769 PMC: 11305784. DOI: 10.1097/MS9.0000000000002276.


Can modulation of gut microbiota affect anthropometric indices in patients with non-alcoholic fatty liver disease? An umbrella meta-analysis of randomized controlled trials.

Amini-Salehi E, Nayak S, Maddineni G, Mahapatro A, Keivanlou M, Soltani Moghadam S Ann Med Surg (Lond). 2024; 86(5):2900-2910.

PMID: 38694388 PMC: 11060227. DOI: 10.1097/MS9.0000000000001740.


Harnessing Vaginal Probiotics for Enhanced Management of Uterine Disease and Reproductive Performance in Dairy Cows: A Conceptual Review.

Adnane M, Whiston R, Tasara T, Bleul U, Chapwanya A Animals (Basel). 2024; 14(7).

PMID: 38612312 PMC: 11011061. DOI: 10.3390/ani14071073.


Canaries' Microbiota: The Gut Bacterial Communities along One Female Reproductive Cycle.

Hattab J, Marruchella G, Sibra A, Tiscar P, Todisco G Microorganisms. 2023; 11(9).

PMID: 37764133 PMC: 10537324. DOI: 10.3390/microorganisms11092289.